Victor Vlad Babeş

Dr. Victor Vlad Babeş


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2025 in Medical Sciences
Verified
Journal Article
Open access
PDF file
EBElena Emilia Babes
Elena Emilia Babes
ARAndrei-Flavius Radu
Andrei-Flavius Radu
NCNoemi Adaus Cretu
Noemi Adaus Cretu
GBGabrielas Bungau
Gabrielas Bungau
Camelia DiaconuCamelia Diaconu
Camelia Diaconu
VBVictor Vlad Babeş
Victor Vlad Babeş
Background/Objectives: Inflammation plays a key role in acute coronary syndromes (ACS). The systemic immune-inflammation index (SII), which integrates immune and inflammatory markers, may serve as a valuable prognostic tool. This study aimed to evaluate the utility of SII as a short-term predictor of mortality and major adverse cardiovascular and cerebral events (MACCE) in ACS patients. Methods: A retrospective analysis was conducted on 964 ACS patients admitted in 2023. SII was calculated from admission hematological parameters. Primary and secondary outcomes were 30-day mortality and MACCE, respectively. Results: SII levels differed significantly across ACS subtypes (p < 0.001), highest in ST-segment elevation myocardial infarction (STEMI) and lowest in unstable angina. SII was markedly higher in deceased patients (2003.79 ± 1601.17) vs. survivors (722.04 ± 837.25; p < 0.001) and remained an independent predictor of mortality (OR = 1.038, p < 0.001). Similarly, SII was elevated in MACCE cases (1717 ± 1611.32) vs. non-MACCE (664.68 ± 713.11; p < 0.001) and remained predictive in multivariate analysis (OR = 1.080, p < 0.001). Predictive accuracy for MACCE was moderate (AUC = 0.762), improved when combined with GRACE 2, especially in specificity (p = 0.07). In STEMI, SII had excellent accuracy (AUC = 0.874), outperforming neutrophil–lymphocyte ratio and C-reactive protein. SII rose at 24 h and declined at 48 h in STEMI, with a slower decline in MACCE patients. Conclusions: SII proved to be a cost-effective biomarker reflecting inflammation, immunity, and thrombosis. Elevated SII predicted short-term MACCE and mortality in ACS, with improved prognostic power when combined with GRACE 2. Persistent elevation may signal ongoing inflammation and increased MACCE risk.

17 June 2025 in Medicina
Verified
Journal Article
Open access
PDF file
EBElena Emilia Babes
Elena Emilia Babes
ARAndrei-Flavius Radu
Andrei-Flavius Radu
VBVictor Vlad Babeş
Victor Vlad Babeş
PBPaula Blaj-Tunduc
Paula Blaj-Tunduc
ARAda Radu
Ada Radu
Cristiana BusteaCristiana Bustea
Cristiana Bustea
Background and Objectives: Assessing risk is essential for optimal care in acute pulmonary embolism (PE). The present research seeks to evaluate the value of admission blood cellular indices as predictors of in-hospital outcome in acute PE and their utility in conjunction with validated risk tools such as the Pulmonary Embolism Severity Index (PESI) score and the European Society of Cardiology (ESC) risk stratification. Materials and Methods: A total of 1058 individuals hospitalized at Bihor County Emergency Hospital, Oradea, Romania, with a diagnosis of acute PE confirmed by contrast-enhanced computed tomographic pulmonary angiography were retrospectively evaluated. Results: A total of 165 patients (18.2%) experienced adverse outcomes, including in-hospital mortality, cardiac arrest, cardiogenic shock, or persistent hypotension, and required rescue thrombolytic therapy. The neutrophil-to-lymphocyte ratio (NLR) was an independent predictor for in-hospital adverse outcome OR = 1.071 (95% CI 1.01–1.137), p < 0.001. NLR as a predictor of adverse outcome had an AUC of 0.712 (95% CI 0.661–0.742), p < 0.001, sensitivity of 72.56%, and specificity of 64.19% for a cutoff value of >5.493. In a combined model with PESI or with ESC risk classification, NLR is leading to a significant improvement in their AUC (p < 0.001). Conclusions: Among hematological markers, NLR holds the greatest relevance for stratifying risk in acute pulmonary embolism and serves as an independent indicator of unfavorable in-hospital prognosis. NLR had an acceptable discriminative power to predict short-term complications and can increase the predictive value of the PESI score and of ESC risk classification.

12 August 2025 in Medicina
Verified
Journal Article
Open access
PDF file
PBPaula Blaj-Tunduc
Paula Blaj-Tunduc
CBCiprian Brisc
Ciprian Brisc
CBCristina Mihaela Brisc
Cristina Mihaela Brisc
DANA CARMEN ZAHADANA CARMEN ZAHA
DANA CARMEN ZAHA
Cristiana BusteaCristiana Bustea
Cristiana Bustea
EBElena Emilia Babes
Elena Emilia Babes
Background/Objectives: Heart failure (HF) with reduced ejection fraction (EF) has, in more than 50% of cases, an ischemic etiology and continues to be associated with increased mortality and morbidity despite all the progress registered in the field of medical therapy and interventional revascularization. Myocardial revascularization is extensively used in clinical practice based on the traditional concept that it can improve myocardial function and outcome in ischemic HF. This review is aimed at presenting current knowledge regarding revascularization in patients with chronic ischemic HF and reduced EF. Methods: The impact of revascularization on symptomatology, left ventricle reverse remodeling, major adverse cardiac events (MACEs), and the role of complete revascularization and of percutaneous interventional revascularization in chronic total occlusion (PCI-CTO) were analyzed. The best therapeutic strategies, revascularization and/or optimal medical therapy (OMT), are debated in different categories of patients, in order to identify who will benefit more from revascularization strategies. Results: Based on the long-term results of the STICH trial incorporated in the guidelines with a class I-b recommendation, coronary artery bypass graft (CABG) remains the main modality of revascularization for prognostic improvement in ischemic HF with multivessel disease. But real-life patients are usually old with multiple comorbidities and high surgical risk. In this category, the Heart Team opinion is required to evaluate the probability of complete revascularization and to choose between percutaneous coronary intervention (PCI) and CABG according to clinical status and coronary anatomy. Conclusions: However, until further studies are available, the results of the REVIVED-BCIS2 trial encourage OMT over PCI in patients with ischemic cardiomyopathy. The available randomized controlled trials (RCTs) showed improved angina and quality of life in PCI-CTO versus OMT, but the effect on MACEs was not demonstrated.

2 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IOANA ADELA RATIUIOANA ADELA RATIU
IOANA ADELA RATIU
VBVictor Vlad Babeş
Victor Vlad Babeş
OHOzana Hocopan
Ozana Hocopan
CRCristian Adrian Ratiu
Cristian Adrian Ratiu
CCCamelia Anca Croitoru
Camelia Anca Croitoru
EBElena Emilia Babes
Elena Emilia Babes
Background: Heart failure (HF) is highly prevalent among patients on maintenance hemodialysis (HD) and contributes substantially to morbidity and mortality. This study aimed to evaluate the prevalence, clinical characteristics, and prognostic impact of HF in a chronic HD population. Methods: A single-center observational study was conducted on 271 HD patients (January 2022–September 2024). HF was defined and classified according to 2021 ESC criteria using echocardiography and NT-proBNP. Clinical, laboratory, and dialysis parameters were compared between HF and non-HF patients. Predictors of HF were assessed using multivariable logistic regression, and survival analyses were performed using Cox regression and Kaplan–Meier curves. Results: HF was identified in 75% of patients: 45% had a preserved EF, 31% had a mildly reduced EF, and 24% had a reduced EF. HF patients were older, had higher NT-proBNP, lower EF, more atrial fibrillation, CAD, and increased interdialytic weight gain. In the multivariable analysis, a reduced EF (OR = 0.77, p = 0.001), older age (OR = 1.12, p = 0.001), and UF rate (OR = 1.31, p = 0.02) were found to independently predict HF. During the 34-month follow-up, HF was found to be associated with significantly higher all-cause and cardiac mortality and more frequent HF-related hospitalizations (log-rank p < 0.001). In the multivariable Cox regression, two variables were found to independently predict all-cause death, NT-proBNP (per 1000 pg/mL) (HR 1.030, p = 0.029) and a lower EF: (HR 0.97, p = 0.019). For cardiac death, a higher NT-proBNP (HR 1.038, p = 0.033) and a lower EF (HR 0.933, p = 0.001) together with a lower BMI (HR = 0.929, p = 0.028) persisted as independent predictors. Conclusions: HF is extremely common in HD patients and identifies a subgroup with distinct clinical characteristics and poor prognosis. NT-proBNP and left ventricular ejection fraction are key independent predictors of mortality, underscoring the importance of early cardiac evaluation and integrated volume and dialysis management to improve outcomes.

11 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IOANA ADELA RATIUIOANA ADELA RATIU
IOANA ADELA RATIU
MBMihaela Cristina Brisc
Mihaela Cristina Brisc
AEAlina Daciana Elec
Alina Daciana Elec
MCMoisa Corina
Moisa Corina
ARAnamaria Ratiu
Anamaria Ratiu
EBElena Emilia Babes
Elena Emilia Babes
Background: Cardiovascular disease remains a leading cause of morbidity and mortality after kidney transplantation. The relative contribution of metabolic abnormalities and inflammatory burden to cardiac remodeling and subsequent clinical outcomes in kidney transplant recipients (KTRs) remains incompletely understood. Methods: In this retrospective cohort study, 152 KTRs underwent comprehensive cardiovascular evaluation at a stable post-transplant time point (12 ± 4 months after transplantation). Metabolic phenotype was assessed using metabolic syndrome and indices of insulin resistance and atherogenic dyslipidemia (TyG index, TG/HDL ratio, and atherogenic index of plasma [AIP]). Inflammatory status was evaluated using hs-CRP and complete blood count-derived indices. Echocardiographic damage composite (EDC) was defined as the presence of left ventricular hypertrophy, diastolic dysfunction, or left atrial enlargement. Patients were followed for major adverse clinical outcome (MACO), defined as cardiovascular event, graft failure, or death, and major adverse cardiovascular and cerebrovascular events (MACCE). Results: At baseline, 78 patients (51.3%) met criteria for EDC. EDC was strongly associated with higher TyG, AIP, TG/HDL, LDL/HDL ratio, and metabolic syndrome, whereas inflammatory markers showed no association. In multivariable logistic regression adjusted for age, sex, eGFR, and proteinuria, TyG remained independently associated with EDC (OR 1.13 per 0.1 increase, 95% CI 1.05–1.21; p = 0.001), independent of hs-CRP. Similar results were observed when AIP was evaluated in place of TyG (OR 10.39, 95% CI 2.22–48.71; p = 0.003). During follow-up, 78 patients developed MACO and 49 developed MACCE. In Cox regression analysis, graft dysfunction and inflammatory markers independently predicted MACO, whereas TyG was no longer significant. In contrast, TyG remained an independent predictor of MACCE after adjustment for confounders and inflammatory markers (HR 1.10 per 0.1 increase, 95% CI 1.04–1.16; p < 0.001). Similar results were observed when AIP was tested in place of TyG (HR 10.8, 95% CI 3.06–38.11; p < 0.001). Echocardiographic damage did not independently predict outcomes after adjustment. Conclusions: In KTRs, metabolic abnormalities reflecting insulin resistance and atherogenic dyslipidemia are closely associated with cardiac remodeling one year after transplantation and remain specifically linked to subsequent cardiovascular events. In contrast, systemic inflammation and graft dysfunction are the primary determinants of overall adverse clinical outcomes. Simple metabolic indices such as TyG and AIP may provide practical tools for cardiovascular risk stratification in this population. In Cox proportional hazards models, TyG (HR 1.102, 95% CI 1.043–1.164, p = 0.001) and AIP (HR 10.8, 95% CI 3.06–38.11, p < 0.001) were independently associated with cardiovascular events during follow-up, underscoring the role of atherogenic dyslipidemia in cardiovascular risk.

13 July 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
AHAlexandra Herlas-Pop
Alexandra Herlas-Pop
ARAndrei-Flavius Radu
Andrei-Flavius Radu
ARAda Radu
Ada Radu
GBGabrielas Bungau
Gabrielas Bungau
Delia Mirela TitDelia Mirela Tit
Delia Mirela Tit
EBElena Emilia Babes
Elena Emilia Babes
Background/Objectives: Depression is a frequent but underrecognized comorbidity in ST-segment elevation myocardial infarction (STEMI) and is associated with adverse cardiovascular outcomes. The interplay between pre-existing depression, systemic inflammation, and major adverse cardiovascular and cerebrovascular events (MACCE) in STEMI remains insufficiently explored. This study aimed to investigate this interplay in a cohort of patients with STEMI. Methods: This retrospective observational cohort study included 292 consecutive patients with STEMI admitted between September 2023 and September 2024. Depression was identified through pre-existing psychiatric diagnoses. Inflammatory markers (C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII)) and echocardiographic parameters, including left ventricular ejection fraction (LVEF), were collected at baseline and 12-month follow-up. In-hospital and 12-month MACCE were defined as composite endpoints. Results: Depression was present in 21.2% of patients. Patients with depression exhibited significantly higher CRP, NLR, SII, 48-h troponin levels, no-reflow incidence, and longer hospitalization. In-hospital MACCE occurred in 24.2% versus 11.7% of patients (p = 0.014), driven mainly by recurrent myocardial infarction, with a trend toward severe heart failure. At 12 months, MACCE occurred in 53.22% of patients with depression versus 23.5% of patients without (p < 0.001). Independent predictors of 12-month MACCE included depression (OR 3.35), baseline SII (OR 4.89 per 1000 units), baseline CRP (OR 1.48 per 10 mg/L), and 12-month LVEF (OR 0.69 per 5% increase). No significant interaction was observed between depression and inflammatory or functional parameters. Conclusions: Pre-existing depression was independently associated with increased in-hospital and 12-month MACCE risk in patients with STEMI. Future prospective studies should assess whether treating depression improves long-term STEMI outcomes.